欢迎来到 CSNpharm! 产品仅用于科研!
首页 Compound Arrays 促销产品
400-920-2911 sales@csnpharm.cn    

Aldose Reductase

Aldose Reductase

货号 产品名 CAS号 信息
CSN12110 Tolrestat 82964-04-3 Tolrestat is a potent, orally active aldose reductase inhibitor with IC50 value of 35 nM.
CSN17888 Ranirestat 147254-64-6 Ranirestat is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy.
CSN22130 Fidarestat 136087-85-9 Fidarestat is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat has the potential to treat diabetic disease.
CSN12976 Epalrestat 82159-09-9 Epalrestat is an aldose reductase inhibitor with IC50 of 72 nM, and used for the treatment of diabetic neuropathy.
CSN14844 Dehydroglyasperin D 517885-72-2 Dehydroglyasperin D, a natural product isolated and purified from the roots of Glycyrrhiza uralensis with anti-obesity, antioxidant, anti-aldose reductase, anticancer, anti-inflammator and strong ferric reducing activities, inhibits the proliferation of HT-29 human colorectal cancer cells through direct interaction with phosphatidylinositol 3-kinase, mediates suppression of both COX-2 expression and the MLK3 signalling pathway through direct binding and inhibition of MLK3, effectively scavenges DPPH, ABTS(+), and singlet oxygen radicals.
CSN18314 Alrestatin Sodium 51876-97-2 Alrestatin sodium is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
CSN10270 Alrestatin 51411-04-2 Alrestatin is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
CSN17745 Aldose Reductase-IN-1 1355612-71-3 Aldose reductase-IN-1 is an inhibitor of aldose reductase with IC50 of 28.9 pM.
CSN23670 3-bromo-5-phenyl Salicylic Acid 4906-68-7 3-bromo-5-phenyl Salicylic Acid is a cell-permeable salicylic acid compound that acts as a highly potent, active-site directed and substrate competitive AKR1C1 inhibitor (Ki = 4 nM) with moderate to excellent selectivity over AKR1C2, AKR1C3 and AKR1C4 (Ki = 0.087, 4.2 and 18.2 µM, respectively).
<< PREV 1 NEXT >>